[EN] COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION<br/>[FR] POLYTHÉRAPIE POUR LE TRAITEMENT DU CANCER ET L'IMMUNOSUPPRESSION
申请人:BASILEA PHARMACEUTICA AG
公开号:WO2014009222A1
公开(公告)日:2014-01-16
The invention relates to novel Rauwolfia alkaloid derivatives of formula (I) combinations of Rauwolfia alkaloid derivatives and a mitochondrial inhibitor, e.g. metformin, and the use of Rauwolfia alkaloid derivatives in combination with mitochondrial inhibitor for the treatment of cancer and for achieving clinical immunosuppression. The invention also relates to a fluorescence-based method for predicting the sensitivity of a cancer cell towards a compound of formula (I).
designing a selective fluorescence chemosensor for the determination of trace amounts of Cr3+ ions in acetonitrile–water (MeCN/H2O (90:10, %v/v) solutions. The intensity of the fluoresce emission of the chemosensor is intensified upon addition of Cr3+ ions in MeCN/H2O (90:10, %v/v) solutions, due to the formation of a selective 1:1 complex between L and Cr3+ ions. The fluorescence enhancement versus Cr3+
Two-step FRET mediated metal ion induced signalling responses in a probe appended with three fluorophores
作者:Biswonath Biswal、Ajoy Pal、Bamaprasad Bag
DOI:10.1039/c7dt01592e
日期:——
A tri-fluorophore appended Tren receptor based probe exhibited chelation induced ratiometric fluorescence signalling through a two-step FRET process; enhancement of FAn→ FRhenergy transfer efficiency through an FNBDintermediate was observed.
COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION
申请人:Basilea Pharmaceutica AG
公开号:US20150157622A1
公开(公告)日:2015-06-11
The invention relates to novel Rauwolfia alkaloid derivatives of formula (I) combinations of Rauwolfia alkaloid derivatives and a mitochondrial inhibitor, e.g. metformin, and the use of Rauwolfia alkaloid derivatives in combination with mitochondrial inhibitor for the treatment of cancer and for achieving clinical immunosuppression. The invention also relates to a fluorescence-based method for predicting the sensitivity of a cancer cell towards a compound of formula (I).
Chain length effect of spiro-ring <i>N</i>-alkylation on photophysical signalling parameters in Fe(<scp>iii</scp>) selective rhodamine probes
作者:Suryakanta Dehuri、Santosh Kumar Mishra、Bamaprasad Bag
DOI:10.1039/d2ob00194b
日期:——
few molecular probes based on the rhodamine B (1–5) and rhodamine 6G (6–10) platform were synthesized by their derivatization with n-alkyl substituents of varying chain lengths at the amino-donor of their spiro-ring end, which exhibited Fe(III)-selective absorption and fluorescence ‘off–on’ signal transduction along with colorization of solution. The Fe(III)-selectivity in these probes remained the
在罗丹明衍生物中表现出络合诱导的螺环开环的光物理信号参数对于实现痕量选择性金属离子检测至关重要。各种官能团的取代,例如对核心结构的烷基化,可调节此类分子探针的物理化学性质。尽管进行了一些研究,光物理信号调制的程度与正烷基取代基的链长之间的关系仍然难以捉摸。在本研究中,基于罗丹明 B ( 1-5 ) 和罗丹明 6G ( 6-10 ) 平台的一些分子探针通过它们与n的衍生化合成。-在其螺环末端的氨基供体处具有不同链长的烷基取代基,其表现出Fe(III)选择性吸收和荧光“关-开”信号转导以及溶液的着色。这些探针中的 Fe( III )-选择性保持不变,尽管它们的结构因取代基的不同正烷基链长度而有所不同;然而,分析了可量化的信号参数,如光谱增强因子、灵敏度、螺环开环动力学和探针-Fe( III )相互作用的有效性。这些参数也与n的不同链长的影响相关-烷基取代基有效地促进了它们的组分间相互作用的立体电子环境。